COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

[1]  R. Walter.  Investigational CD33-targeted therapeutics for acute myeloid leukemia , 2018, Expert opinion on investigational drugs.

[2]  N. Gökbuget,et al.  Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab , 2017, Expert opinion on drug safety.

[3]  R. Gale,et al.  Gemtuzumab ozogamicin in acute myeloid leukemia , 2017, Leukemia.

[4]  A. Wolf,et al.  Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications , 2016, Clinical Pharmacokinetics.

[5]  J. Guenot,et al.  Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia , 2016, Clinical Cancer Research.

[6]  C. Klein,et al.  A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors , 2016, Clinical Cancer Research.

[7]  S. Brack,et al.  A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action , 2014, Molecular Cancer Therapeutics.

[8]  A. Henn,et al.  Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.

[9]  W. Hiddemann,et al.  CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. , 2014, Blood.

[10]  G. Ehninger,et al.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system , 2014, Leukemia.

[11]  A. Mackensen,et al.  T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct , 2013, Leukemia.

[12]  S. Raimondi,et al.  Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy , 2013, Clinical Cancer Research.

[13]  W. Hiddemann,et al.  MYELOID NEOPLASIA CD 33 target validation and sustained depletion of AML blasts in long-term cultures by the bispeci fi c T-cell – engaging antibody AMG 330 , 2013 .

[14]  D. Banner,et al.  Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain , 2012, mAbs.

[15]  D. Neri,et al.  A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties* , 2007, Journal of Biological Chemistry.

[16]  H. Oettgen,et al.  The T3/T cell receptor complex: antigenic distinction between the two 20‐kd T3 (T3‐delta and T3‐epsilon) subunits. , 1985, The EMBO journal.